Vaccines

Researchers aimed to quantify the amount of protection maternal COVID-19 boosters provide during the first 6 months of an infant’s life.

In a prospective study, researchers evaluated the immune response and adverse events of COVID-19 and seasonal influenza vaccine coadministration.

This COVID-19 roundup includes coverage on the outcomes associated with two omicron subvariant treatments, FDA’s authorization of Novavax vaccine, the NIH Treatment Guidelines Panel’s recommendation of...

Findings show that children in early childhood are not completing their multidose vaccine series due to some structural barriers.

The FDA approved the new round of vaccines for those 12 years and older and authorized emergency use for children 6 months to 11 years of age.

Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

This COVID-19 roundup includes a summary of studies on the effective treatment options for patients with long COVID, the risk of patients developing medical or mental health conditions post-hospitalization...

This COVID-19 roundup includes coverage of the FDA’s simpler vaccination schedule and authorization of new treatment, decline in pediatric asthma diagnoses during pandemic, and a new treatment combination...

This COVID-19 roundup includes coverage of the FDA’s amendment to its emergency use authorization of the Pfizer-BioNTech booster for pediatric patients, acute myocardial infection deaths rose during omicron...